IRIS
RIMASSA, Lorenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.399
AS - Asia 8.269
EU - Europa 3.321
SA - Sud America 1.665
Continente sconosciuto - Info sul continente non disponibili 554
AF - Africa 351
OC - Oceania 24
AN - Antartide 2
Totale 28.585
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.009
SG - Singapore 4.972
CN - Cina 1.440
BR - Brasile 1.374
IT - Italia 1.235
VN - Vietnam 806
FI - Finlandia 454
IE - Irlanda 335
DE - Germania 311
HK - Hong Kong 246
CA - Canada 235
FR - Francia 213
NG - Nigeria 206
GB - Regno Unito 179
IN - India 175
NL - Olanda 134
BD - Bangladesh 125
AR - Argentina 113
SE - Svezia 88
TR - Turchia 82
MX - Messico 81
IQ - Iraq 62
RU - Federazione Russa 56
JP - Giappone 52
ID - Indonesia 50
ZA - Sudafrica 44
CL - Cile 43
EC - Ecuador 41
BE - Belgio 38
PL - Polonia 38
IL - Israele 37
ES - Italia 36
UA - Ucraina 36
AT - Austria 34
CO - Colombia 34
PK - Pakistan 31
SA - Arabia Saudita 26
UZ - Uzbekistan 24
MA - Marocco 23
AU - Australia 21
VE - Venezuela 21
PH - Filippine 19
EG - Egitto 18
LT - Lituania 17
CZ - Repubblica Ceca 15
JM - Giamaica 15
KE - Kenya 15
PY - Paraguay 15
AZ - Azerbaigian 14
DZ - Algeria 14
NP - Nepal 14
PT - Portogallo 13
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
CR - Costa Rica 11
IR - Iran 11
JO - Giordania 10
TN - Tunisia 10
KR - Corea 9
PE - Perù 9
BY - Bielorussia 8
CH - Svizzera 8
EU - Europa 8
HN - Honduras 8
KZ - Kazakistan 8
MY - Malesia 8
NO - Norvegia 8
MD - Moldavia 7
SV - El Salvador 7
AL - Albania 6
BG - Bulgaria 6
ET - Etiopia 6
GR - Grecia 6
HR - Croazia 6
KG - Kirghizistan 6
RO - Romania 6
TT - Trinidad e Tobago 6
DO - Repubblica Dominicana 5
GT - Guatemala 5
LB - Libano 5
NI - Nicaragua 5
RS - Serbia 5
BA - Bosnia-Erzegovina 4
HU - Ungheria 4
LV - Lettonia 4
OM - Oman 4
PA - Panama 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
BB - Barbados 3
BH - Bahrain 3
KH - Cambogia 3
ML - Mali 3
PS - Palestinian Territory 3
AQ - Antartide 2
BO - Bolivia 2
GA - Gabon 2
MK - Macedonia 2
MT - Malta 2
Totale 28.010
Salva come PNG Salva come JPEG
Città #
Singapore 2.170
Dallas 1.783
Wilmington 1.296
Chandler 1.287
Ashburn 961
The Dalles 632
San Jose 611
Shanghai 565
Milan 536
San Mateo 477
Council Bluffs 459
Helsinki 454
New York 397
Ann Arbor 394
Beijing 364
Dublin 333
Ho Chi Minh City 285
Princeton 270
Lawrence 253
Boardman 244
Santa Clara 242
Leawood 232
Los Angeles 226
Hong Kong 221
Benin City 205
Rome 195
Hanoi 179
Paris 146
Buffalo 121
Amsterdam 110
Fairfield 108
Woodbridge 108
São Paulo 104
Toronto 99
London 86
Phoenix 86
Columbus 65
Seattle 61
Chicago 53
Naples 51
Orem 47
Figino 44
Montreal 44
San Diego 44
Rio de Janeiro 42
Kocaeli 39
Brooklyn 37
Da Nang 37
Belo Horizonte 36
Haiphong 36
Brussels 35
Charlotte 35
Falkenstein 35
Tokyo 35
Mexico City 34
Brasília 32
Chennai 32
Pune 32
Abbiategrasso 31
Munich 31
Redwood City 31
Warsaw 31
Norwalk 30
Turin 29
Assago 28
Houston 27
Salvador 27
Boston 26
Miami 23
San Francisco 23
Atlanta 22
Baghdad 22
Curitiba 22
Philadelphia 22
Tashkent 22
Porto Alegre 21
Hải Dương 20
Manchester 20
Milwaukee 20
Queens 20
Dhaka 19
Johannesburg 19
Campinas 18
Guayaquil 18
Frankfurt am Main 17
Las Vegas 17
Florence 16
Moscow 16
Pasadena 16
Guarulhos 15
Redmond 15
St Louis 15
Baku 14
Jeddah 14
Mumbai 14
Ninh Bình 14
Ribeirão Preto 14
Andover 13
Biên Hòa 13
Cincinnati 13
Totale 18.003
Salva come PNG Salva come JPEG
Nome #
Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis 314
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment 272
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 196
Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report 171
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 163
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 159
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 155
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 151
5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors 145
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 142
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 139
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 137
Tivantinib for hepatocellular carcinoma 132
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 132
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 131
Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSC 130
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 130
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 124
Tumor-associated macrophages and response to 5-flourouracil adjuvant therapy in stage III colorectal cancer 124
Biomarkers in Hepatocellular Carcinoma-Letter 123
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 120
Can SBRT improve the prognosis of unresectable pancreatic cancer? Clinical results on 106 patients 118
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 117
Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 116
COVID-19 and liver cancer clinical trials: not everything is lost 115
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 115
Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival. 115
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 113
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 113
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 112
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 109
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 109
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 109
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 108
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 107
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 107
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 107
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 107
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 106
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 104
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 104
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial 103
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole 103
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 103
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 102
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 100
Antiangiogenic drugs currently used for colorectal cancer: What other pathways can we target to prolong responses? 100
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 100
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 100
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 99
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 99
Cabozantinib for the treatment of hepatocellular carcinoma 98
Medical Oncologists must get more involved in systemic treatment of Hepatocellular Carcinoma 98
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. 98
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98 98
High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models 98
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 98
Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses 97
Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms 97
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 96
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 96
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer 95
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 95
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 94
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 94
FOLFOX/CAPOX in stage II–III colon cancer: efficacy results of the Italian Three Or Six Colon Adjuvant trial (TOSCA) 94
Characterisation of the immune-related transcriptome in resected biliary tract cancers 94
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 93
Prognostic value of the immune-related transcriptome in biliary tract cancers 93
Reply to Y. Pointreau et al 93
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 93
From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology 92
Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib 92
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 92
Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer 92
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 91
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 91
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 91
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 91
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 90
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 90
Chemotherapy with mitomycin c and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin 90
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 90
Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers 90
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. 90
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up 89
Neuroendocrine differentiation in solid tumors 89
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 89
Shaping the landscape of immune oncology in hepatocellular carcinoma 88
Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial 88
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 88
Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab 88
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 87
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 87
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 87
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma 87
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 86
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 86
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial 86
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 86
Totale 11.005
Salva come PNG Salva come JPEG
Categoria #
all - tutte 173.404
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 173.404
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.443 0 43 20 316 28 33 70 219 136 211 270 97
2022/20233.786 563 174 342 440 302 293 35 310 675 355 257 40
2023/20242.440 161 251 455 89 76 341 161 127 36 53 278 412
2024/20253.714 121 62 29 57 75 432 284 337 580 794 424 519
2025/202612.353 1.462 1.455 1.081 1.192 339 527 2.794 506 535 768 675 1.019
2026/20272.250 1.359 891 0 0 0 0 0 0 0 0 0 0
Totale 28.585